drugset / Trial / NCT02878863

Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis

NCT02878863

Phase 3 Withdrawn Xiaoli Fan
RandomizedParallel-groupOpen-labelTreatment

Summary

An open-label,prospective, randomized pilot study to evaluate the efficacy, safety and tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (AIH) with mild necroinflammatory activity on liver biopsy.

Timeline

Start
2016-08
Primary completion
2017-03
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Paeoniflorin Small molecule 600 mg
Background Choline Other / unclassified
Background Silymarin Traditional medicine (herbal / TCM)

Indications